Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited (CLVLY) Financial Performance & Income Statement Overview
Explore the financials of Clinuvel Pharmaceuticals Limited (CLVLY), including yearly and quarterly data on income, cash flow, and balance sheets.
Clinuvel Pharmaceuticals Limited (CLVLY) Income Statement & Financial Overview
View the income breakdown for Clinuvel Pharmaceuticals Limited CLVLY across both annual and quarterly reports.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $35.65M | $55.38M | $32.26M | $48.97M |
| Cost of Revenue | $3.06M | $5.29M | $15.34M | $15.47M |
| Gross Profit | $32.59M | $50.09M | $16.92M | $33.49M |
| Gross Profit Ratio | $0.91 | $0.90 | $0.52 | $0.68 |
| R&D Expenses | $2.84M | $1.60M | $752499.00 | $678203.00 |
| SG&A Expenses | $12.87M | $13.82M | $4.84M | $4.88M |
| Operating Expenses | $15.71M | $15.41M | $5.59M | $5.56M |
| Total Costs & Expenses | $18.77M | $23.70M | $20.92M | $21.04M |
| Interest Income | $0.00 | $3.66M | $3.66M | $2.57M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $607839.00 | $177754.00 | $575430.00 | $413322.00 |
| EBITDA | $16.88M | $34.85M | $14.47M | $29.89M |
| EBITDA Ratio | $0.47 | $0.63 | $0.45 | $0.58 |
| Operating Income | $16.88M | $32.22M | $11.33M | $27.93M |
| Operating Income Ratio | $0.47 | $0.58 | $0.35 | $0.57 |
| Other Income/Expenses (Net) | $5.05M | $3.65M | $332689.00 | $3.05M |
| Income Before Tax | $21.93M | $35.87M | $14.81M | $30.98M |
| Income Before Tax Ratio | $0.62 | $0.65 | $0.46 | $0.63 |
| Income Tax Expense | $7.86M | $11.17M | $3.87M | $11.76M |
| Net Income | $14.08M | $24.70M | $10.94M | $19.22M |
| Net Income Ratio | $0.39 | $0.45 | $0.34 | $0.39 |
| EPS | $0.28 | $0.49 | $0.22 | $0.39 |
| Diluted EPS | $0.28 | $0.49 | $0.21 | $0.37 |
| Weighted Avg Shares Outstanding | $50.27M | $50.51M | $50.13M | $49.41M |
| Weighted Avg Shares Outstanding (Diluted) | $50.27M | $50.47M | $51.59M | $51.85M |
Over the last four quarters, Clinuvel Pharmaceuticals Limited achieved steady financial progress, growing revenue from $48.97M in Q4 2023 to $35.65M in Q2 2025. Gross profit stayed firm with margins at 91% in Q2 2025 versus 68% in Q4 2023. Operating income totaled $16.88M in Q2 2025, maintaining a 47% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at $16.88M. Net income dropped to $14.08M, with EPS at $0.28. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan